Applications of SPECT imaging of dopaminergic neurotransmission in neuropsychiatric disorders

被引:37
作者
Kugaya, A
Fujita, M
Innis, RB
机构
[1] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[2] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA
[3] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA
关键词
single photon emission computed tomography (SPECT); dopamine; Parkinson's disease; schizophrenia;
D O I
10.1007/BF02990472
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Single photon emission computed tomography (SPECT) tracers selective for pre- and post-synaptic targets have allowed measurements of several aspects of dopaminergic (DA) neurotransmission. In this article, we will first review our DA transporter imaging in Parkinson's disease. We have developed the in vivo dopamine transporter(DAT) imaging with [I-123]beta-CIT ((1R)-2 beta-Carbomethoxy-3 beta-(4-iodophenyl)tropane). This method showed that patients with Parkinson's disease have markedly reduced DAT levels in striatum, which correlated with disease severity and disease progression. Second, we applied DA imaging techniques in patients with schizophrenia. Using amphetamine as a releaser of DA, we observed the enhanced DA release, which was measured by imaging D2 receptors with [I-123]IBZM (iodobenzamide), in schizophrenics. Further we developed the measurement of basal synaptic DA levels by AMPT (alpha-methyl-paratyrosine)-induced unmasking of D2 receptors. Finally, we expanded our techniques to the measurement of extrastriatal DA receptors using [I-123]epidepride. The findings suggest that SPECT is a useful technique to measure DA transmission in human brain and may further our understanding of the pathophysiology of neuropsychiatric disorders.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 71 条
[41]  
LEENDERS KL, 1995, NEUROLOGY, V45, pA220
[42]   THE NIGROSTRIATAL DOPAMINERGIC SYSTEM ASSESSED INVIVO BY POSITRON EMISSION TOMOGRAPHY IN HEALTHY VOLUNTEER SUBJECTS AND PATIENTS WITH PARKINSONS-DISEASE [J].
LEENDERS, KL ;
SALMON, EP ;
TYRRELL, P ;
PERANI, D ;
BROOKS, DJ ;
SAGER, H ;
JONES, T ;
MARSDEN, CD ;
FRACKOWIAK, RSJ .
ARCHIVES OF NEUROLOGY, 1990, 47 (12) :1290-1298
[43]   PROVOCATIVE TESTS WITH PSYCHOSTIMULANT DRUGS IN SCHIZOPHRENIA [J].
LIEBERMAN, JA ;
KANE, JM ;
ALVIR, J .
PSYCHOPHARMACOLOGY, 1987, 91 (04) :415-433
[44]   [I-123] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease [J].
Marek, KL ;
Seibyl, JP ;
Zoghbi, SS ;
ZeaPonce, Y ;
Baldwin, RM ;
Fussell, B ;
Charney, DS ;
vanDyck, C ;
Hoffer, PB ;
Innis, RB .
NEUROLOGY, 1996, 46 (01) :231-237
[45]   RATE OF CELL-DEATH IN PARKINSONISM INDICATES ACTIVE NEUROPATHOLOGICAL PROCESS [J].
MCGEER, PL ;
ITAGAKI, S ;
AKIYAMA, H ;
MCGEER, EG .
ANNALS OF NEUROLOGY, 1988, 24 (04) :574-576
[46]   An [F-18]dopa-PET and clinical study of the rate of progression in Parkinson's disease [J].
Morrish, PK ;
Sawle, GV ;
Brooks, DJ .
BRAIN, 1996, 119 :585-591
[47]   FLUORINATED BENZAMIDE NEUROLEPTICS .3. DEVELOPMENT OF (S)-N-[(1-ALLYL-2-PYRROLIDINYL)METHYL]-5-(3-[F-18] FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE AS AN IMPROVED DOPAMINE D-2 RECEPTOR TRACER [J].
MUKHERJEE, J ;
YANG, ZY ;
DAS, MK ;
BROWN, T .
NUCLEAR MEDICINE AND BIOLOGY, 1995, 22 (03) :283-296
[48]   TIME-DEPENDENT CHANGES IN DA UPTAKE SITES, D1 AND D2 RECEPTOR-BINDING AND MESSENGER-RNA AFTER 6-OHDA LESIONS OF THE MEDIAL FOREBRAIN-BUNDLE IN THE RAT-BRAIN [J].
NARANG, N ;
WAMSLEY, JK .
JOURNAL OF CHEMICAL NEUROANATOMY, 1995, 9 (01) :41-53
[49]   INCREASED DOPAMINE-RECEPTOR SENSITIVITY IN SCHIZOPHRENIA [J].
OWEN, F ;
CROW, TJ ;
POULTER, M ;
CROSS, AJ ;
LONGDEN, A ;
RILEY, GJ .
LANCET, 1978, 2 (8083) :223-226
[50]   D-2 DOPAMINE-RECEPTOR BINDING IN THE BASAL GANGLIA OF ANTIPSYCHOTIC-FREE SCHIZOPHRENIC-PATIENTS - AN I-123 IBZM SINGLE-PHOTON EMISSION COMPUTERIZED-TOMOGRAPHY STUDY [J].
PILOWSKY, LS ;
COSTA, DC ;
ELL, PJ ;
VERHOEFF, NPLG ;
MURRAY, RM ;
KERWIN, RW .
BRITISH JOURNAL OF PSYCHIATRY, 1994, 164 :16-26